Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Non-Current Debt (2023 - 2025)

Historic Non-Current Debt for Kyntra Bio (KYNB) over the last 3 years, with Q1 2025 value amounting to $73.4 million.

  • Kyntra Bio's Non-Current Debt rose 167.01% to $73.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $73.4 million, marking a year-over-year increase of 167.01%. This contributed to the annual value of $73.1 million for FY2024, which is 160.98% up from last year.
  • Kyntra Bio's Non-Current Debt amounted to $73.4 million in Q1 2025, which was up 167.01% from $73.1 million recorded in Q4 2024.
  • In the past 5 years, Kyntra Bio's Non-Current Debt ranged from a high of $73.4 million in Q1 2025 and a low of $71.4 million during Q2 2023
  • For the 3-year period, Kyntra Bio's Non-Current Debt averaged around $72.4 million, with its median value being $72.3 million (2024).
  • As far as peak fluctuations go, Kyntra Bio's Non-Current Debt skyrocketed by 149.84% in 2024, and later surged by 167.01% in 2025.
  • Kyntra Bio's Non-Current Debt (Quarter) stood at $71.9 million in 2023, then grew by 1.61% to $73.1 million in 2024, then grew by 0.45% to $73.4 million in 2025.
  • Its Non-Current Debt was $73.4 million in Q1 2025, compared to $73.1 million in Q4 2024 and $72.8 million in Q3 2024.